<DOC>
	<DOCNO>NCT02926586</DOCNO>
	<brief_summary>The purpose study determine whether Fludarabine combination cytarabine effective high-dose cytarabine post-remission therapy patient core-binding factor acute myeloid leukemia</brief_summary>
	<brief_title>Fludarabine Cytarabine Versus High-dose Cytarabine CBF-AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Clinical laboratory diagnosis CBFAML , include RUNX1RUNX1T1 CBFMYH11 fusion gene rearrangement PCR/FISH In status complete remission one two course induction therapy Total bilirubinic acid ≤ 35μmol/L , AST/ALT &lt; 2 time abnormal level , serum creatinine &lt; 1.5mg/ml Cardiac function : EF ≥ 50 % Hydroxyurea use patient white blood cell count ≥ 50*109/L ECOG ( Eastern Cooperative Oncology Group ) score : ≤ 2 Relapsed/refractory AML Serious liver/ kidney dysfunction Cardiac function level : 2 Female pregnancy lactation With serious infection disease diseases Not obey principle clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>RUNX1-RUNX1T1</keyword>
	<keyword>CBFβ-MYH11</keyword>
	<keyword>fludarabine</keyword>
	<keyword>cytarabine</keyword>
</DOC>